Among the 35 evaluable patients, the ORR and DCR were 55.6% and 86.1%, with 12-month PFS and OS rates of 42.1% and 63.7%, respectively, confirming that AFP-producing gastric cancer may benefit from PD-1 blockade. The gene discussed is PDCD1; the disease is gastric cancer.